Invo BioScience (INVO)
(Delayed Data from NSDQ)
$0.84 USD
+0.02 (2.18%)
Updated Aug 23, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Invo BioScience Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 0 | 0 | 6 | 10 | 1 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 0 | 0 | 0 | 0 |
Total Current Assets | 1 | 1 | 6 | 11 | 2 |
Net Property & Equipment | 1 | 0 | 1 | 0 | 0 |
Investments & Advances | 3 | 1 | 1 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 10 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 21 | 4 | 10 | 11 | 2 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 2 | 1 | 0 | 1 | 0 |
Accounts Payable | 2 | 1 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 1 | 1 | 1 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3 | 0 | 0 | 1 | 1 |
Total Current Liabilities | 8 | 3 | 1 | 2 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 3 | 4 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 1 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 20 | 5 | 3 | 5 | 6 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 6 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 53 | 49 | 46 | 38 | 20 |
Retained Earnings | -58 | -50 | -39 | -32 | -24 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1 | -1 | 7 | 6 | -4 |
Total Liabilities & Shareholder's Equity | 21 | 4 | 10 | 11 | 2 |
Total Common Equity | -5 | -1 | 7 | 6 | -4 |
Shares Outstanding | 2.40 | 0.60 | 0.50 | 0.40 | 0.20 |
Book Value Per Share | -2.13 | -1.63 | 14.62 | 14.35 | -18.55 |
Fiscal Year End for Invo BioScience Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1 | 0 | 0 | 1 | 0 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 0 | 0 |
Total Current Assets | 2 | 2 | 1 | 2 | 1 |
Net Property & Equipment | 0 | 0 | 1 | 1 | 1 |
Investments & Advances | 3 | 3 | 3 | 1 | 1 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 10 | 10 | 10 | 10 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 18 | 18 | 21 | 19 | 7 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 1 | 2 | 2 | 2 | 1 |
Accounts Payable | 2 | 3 | 2 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 1 | 1 | 1 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3 | 3 | 3 | 0 | 0 |
Total Current Liabilities | 8 | 9 | 8 | 5 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 1 | 1 | 1 | 1 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 5 | 8 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 17 | 18 | 20 | 19 | 8 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 8 | 7 | 6 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 56 | 53 | 53 | 56 | 53 |
Retained Earnings | -62 | -59 | -58 | -56 | -55 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1 | 0 | 1 | 0 | -2 |
Total Liabilities & Shareholder's Equity | 18 | 18 | 21 | 19 | 7 |
Total Common Equity | -6 | -6 | -5 | 0 | -2 |
Shares Outstanding | 3.80 | 2.70 | 2.40 | 2.40 | 0.80 |
Book Value Per Share | -1.62 | -2.40 | -2.13 | 0.15 | -2.14 |